摘要
目的探讨特异性免疫治疗对小儿支气管哮喘合并变应性鼻炎的远期疗效,以期为临床中治疗变应性疾病提供依据。方法选择患有支气管哮喘合并变应性鼻炎患儿48例,采用皮下注射标准化屋尘螨法治疗,从低剂量开始逐渐加量至维持剂量,总疗程3年。比较治疗前与治疗结束时及治疗结束时与随访不同时段的哮喘控制程度、哮喘症状评分、肺功能及鼻部症状评分。分析特异性免疫治疗是否具有确切的远期疗效。结果治疗前与治疗结束时各指标相比,治疗结束时哮喘控制程度(t=3.28)、哮喘症状评分(t=4.04)、肺功能(t=0.08)及鼻部症状评分(t=1.58)较治疗前明显好转,差异具有统计学意义(P<0.05)。治疗结束后半年、1年、2年、3年各指标与治疗结束时相比,变化不大,差异无统计学意义(P>0.05)。结论特异性免疫治疗小儿支气管哮喘合并变应性鼻炎具有远期疗效,可以降低复发率,提高患儿的生活质量。
Objective To explore the long - term effect of specific immunotherapy in treatment of pediatric patients with bronchial asthma and allergic rhinitis, in order to provide evidence for the treatment of allergic diseases. Methods Forty - eight pediatric patients with bronchial asthma and allergic rhinitis were selected for this study. They were treated with standardized therapy of hypodermal injection of house dust mite （HDM） for three years, from low dosage gradually increase the amount to a maintenance dosage. The long - term effect of specific immunotherapy had been analyzed at the time before treatment, post - treatment and follow - up period. Results The indicators at pre - treatment and post - treatment, the degree of asthma control （ t = 3.28 ）, asthma symptom scores （ t = 4.04）, lung function （ t = 0. 08 ） and nose symptom scores （ t = 1.58） before treatment were compared with those after treatment, and the indicators were exactly better then those of pre - treatment, the difference was statistically significant （ P 〈 0.05 ）. There was no difference between follow- up period for half- year, one -year, two -years, three - years after treatment （ P 〉 0. 05 ）. Conclusion Specific immunotherapy （SIT） has long - term effect in treatment of pediatric patients with bronchial asthma and allergic rhinitis, and it can reduce the recurrence rate and raise the quality of life of these pediatric patients.
出处
《临床和实验医学杂志》
2014年第7期568-570,共3页
Journal of Clinical and Experimental Medicine
